A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2024-08-23
Target enrollment:
Participant gender:
Summary
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group,
dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with
moderate to severe plaque psoriasis. This study will evaluate the efficacy, safety,
tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with
moderate to severe plaque psoriasis.